未经批准:在转移性结直肠癌(mCRC)中,迄今为止,免疫检查点阻断(ICB)的疗效仅限于微卫星不稳定性高肿瘤(MSI-H)患者.不幸的是,大多数mCRC患者患有非免疫原性微卫星稳定(MSS)肿瘤。因此,迫切需要新的组合策略来增强MSS肿瘤的免疫原性,以最终增加受益于ICB的患者数量.
UNASSIGNED:AVETUX试验旨在将PD-L1抗体avelumab与标准治疗化疗联合FOLFOX和抗EGFR抗体西妥昔单抗联合使用。此外,我们对治疗前和治疗中的计算机断层扫描进行了中心放射学回顾,以更好地确定个体对治疗的反应.
未经批准:总共,对43例患者进行了治疗,其中39例患者在中央组织检查中被确认为RAS/BRAF野生型,并最终评估了反应。达到最终无进展生存期(PFS)为11.1(范围:0.8至22.3个月)和本文更新的最终总生存期(OS)为32.9个月(范围:0.8至47.1个月)。我们观察到67.5%的肿瘤收缩和反应深度与生存显着相关的强中位反应深度。另一方面,在截止值20%(中位值)时,早期肿瘤缩小并不是预后较好的指标.下一步,我们将个体最佳放射学反应与潜在的ICB反应生物标志物相关联,并发现克隆性和多样性,但不是肿瘤浸润淋巴细胞(TiL)和外周血单核细胞(PBMC)的频率,与反应密切相关。总之,我们报告了AVETUX试验的最终总生存期,并提出T细胞克隆性和多样性作为一个潜在的标志物,通过进行中央放射学回顾,预测MSSmCRC对化学-免疫疗法组合的应答.
未经评估:ClinicalTrials.gov,标识符(NCT03174405)。
UNASSIGNED: In metastatic colorectal cancer (mCRC), the efficacy of immune checkpoint blockade (ICB) has so far been limited to patients with microsatellite instability high tumors (MSI-H). Unfortunately, most mCRC patients suffer from non-immunogenic microsatellite stable (MSS) tumors. Therefore, new combinatorial strategies are urgently needed to enhance the immunogenicity of MSS tumors to finally increase the number of patients benefiting from ICB.
UNASSIGNED: The AVETUX
trial aimed to combine the PD-L1 antibody avelumab with the standard of care chemotherapy combination FOLFOX and the anti-EGFR antibody cetuximab. Furthermore, we performed a central radiological review of the pre- and on-treatment computed tomography scans to better define the individual response to treatment.
UNASSIGNED: In total, 43 patients were treated of which 39 patients were confirmed as RAS/BRAF wildtype in central tissue review and finally response evaluated. A final progression-free survival (PFS) of 11.1 (range: 0.8 to 22.3 months) and a herein updated final overall survival (OS) of 32.9 months (range: 0.8 to 47.1 months) was reached. We observed a strong median depth of response of 67.5% tumor shrinkage and deepness of response correlated significantly with survival. On the other hand, early tumor shrinkage was not an indicator of better outcome at a cut-off of 20% (median values). In a next step, we correlated the individual best radiological response with potential ICB response biomarkers and found that the clonality and diversity, but not frequency of tumor infiltrating lymphocytes (TiLs) and peripheral blood mononuclear cells (PBMCs), strongly correlated with response. In summary, we report the final overall survival of the AVETUX
trial and propose T cell clonality and diversity as a potential marker to predict response to chemo-immunotherapy combinations in MSS mCRC by performing a central radiological review.
UNASSIGNED: ClinicalTrials.gov, identifier (NCT03174405).